Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[MonestHind]

$STSI$ Star Scientific, Inc. New Peer Review Credibility From Johns Hopkins Could Drive Star Scientific Shares Higher

http://tinyurl.com/STSIBreakingNews

Hypothesis no longer: Johns Hopkins scientists now believe they know why Star Scientific's (CIGX) anatabine compound Anatabloc works. Newly presented thyroid research from the peer reviewed journal Endocrinology makes the case. The implications could drive shares sharply higher as peer reviewed substantiation brings new heights of credibility to the science. See below for context and amplification.

This is important breakthrough news from Johns Hopkins University School of Medicine (where the thyroid research and studies have been funded by a grant from the Walton Family Foundation), so slip on your science hat and stay with me on this. The implications from the medical community will now carry new weight as they will be able to officially discern the kind of conditions that anatabine/Anatabloc could be effective in treating.

Autoimmune (so-called "Hashimoto") thyroiditis, first reported in 1912 and considered a rarity until the mid-1950s, has now become the most common of over 100 autoimmune diseases. The list is available here. A Google search of thyroid disease brought up 7,500,000 results.

What is especially interesting is that these autoimmune conditions are precisely those Anatabloc seems to benefit. The multitude of users of Anatabloc already know that it works - so now it becomes "official." Get the picture? Read on.

I have been following and writing about CIGX for over two years, and the shares have gone up over this time frame from just over $1.00 to Friday's close of $4.05 (the shares traded above $5.00 last year and more recently in early July). Obviously the stock has been a big winner, and the science supporting the story has developed to ever more established heights of the 'nigh astonishing': it has progressed from the genesis of discovery to testing, to peer review, to more testing and now to explanation in the leading journal Endocrinology as to "why" it's believed to work.

Human studies remain to be announced; however, Star has said in this regard: "The current impressive results achieved by the Johns Hopkins team strongly support the first look at the thyroid data in man, which we anticipate will be available in the third quarter."

It should be noted that nonbelievers are plentiful regarding the shares of CIGX, as there is a big short interest of 23,622,933 shares, a large percentage of which has been around for well over two years. The number of shares short is up 1,789,378 shares from the last reporting period of two weeks prior. My comment is that much has changed over the last year with the above mentioned impressive news related to anatabine / Anatabloc and it's now a whole new ball game. Shorts should be worried as the remarkable science continues to advance.

Last Tuesday, July 17, in the freshly released Endocrine Society journal Endocrinology, a peer reviewed research abstract was published by the Department of Pathology, Divisions of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, and the Feinstone Department of Molecular Microbiology and Immunology (P.C.) of the Johns Hopkins Bloomberg School of Public Health.